Each of the selected lawsuits involve allegations that the Bard PowerPort system was defectively designed, resulting in life-threatening complications for plaintiffs.
Parties have until the end of January 2025 to finish depositions and fact discovery for potential Bard PowerPort lawsuit bellwether trials.
Inari Medical issued an Urgent Medical Device Labeling Correction last month, which the FDA has declared a Class I medical device recall.
As the federal litigation heads into it's 2nd year, the Court has re-appointed a group of Bard PowerPort lawsuit attorneys to continue serving in leadership positions in the consolidated multidistrict litigation (MDL)
Bellwether claims will be prepared for early trials to help gauge how juries may respond to evidence and testimony that will be repeated throughout more than 300 other Bard Power lawsuits currently pending in the federal court system.
Barium sulfate used in the port catheter tubes cause Xcela infections and failures, according to lawsuit filed by an Arizona woman who required surgical removal of the port.
Lawyers for Bard PowerPort plaintiffs and the manufacturers indicate they are working cooperatively to move through the discovery process and to meet a deadline in 2025 to select claims for early bellwether trials.
Researchers indicate polyurethane catheters, such as those used in Bard PowerPort implants, often lead to early device failure and infections.
This is the latest in a series of massive catheter recalls in recent years, for a variety of defects that have endangered patients' health.
Lawsuit over the Angiodynamics port catheter raises allegations similar to those found in hundreds of Bard PowerPort lawsuits, indicating that device was defectively designed and increases the risk of infections, other injuries.
